A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy
/in Dendritic Cells, International Publications, Pancreatic CancerGene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals
/in Dendritic Cells, HIV/AIDS, International PublicationsOncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis
/in Cervical Cancer, International Publications, Newcastle Disease VirusRadiofrequency deep hyperthermia combined with chemotherapy in the treatment of advanced non-small cell lung cancer
/in Hyperthermia, International Publications, NSCLCA Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials
/in Dendritic Cells, Glioblastoma, International PublicationsCurcumin: New Insights into an Ancient Ingredient against Cancer
/in Curcuma, International PublicationsPersonalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results
/in Dendritic Cells, International Publications, Ovarian CancerVitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer
/in Breast Cancer, International Publications, Micronutrients
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer